Broader policy and market forces—including new legislation, PBM negotiations, and private sector pricing trends—can have significant downstream effects on Non-FAMP and FCP. This session will explore how these evolving external factors influence VA pricing compliance, market access, and commercial strategy.

• Analyzing the impact of policy changes and legislation, including the Inflation Reduction Act (IRA), on pharmaceutical pricing
  • How federal price negotiations under IRA affect brand lifecycles and market prices
• PBM market consolidation and vertical integration—implications for FSS pricing
  • How PBM rebates and formulary positioning affect manufacturer discounts and Non-FAMP calculations
  • How commercial rebate structures influence FSS pricing compliance
• Assessing the impact of tariffs and trade policies on manufacturer pricing strategies
• Understanding the ripple effect of private market dynamics on federal pricing compliance
  • How commercial insurer negotiations impact federal pricing benchmarks
  • The role of biosimilars, generics, and competitive pricing strategies in VA FSS pricing